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BACKGROUND: Heart disease and stroke continue to be
the leading causes of death in the US. As a result, inves-
tigators continue to look for new and emerging bio-
markers of disease risk. Because many of these emerg-
ing biomarkers are not as well documented as those of
conventional lipid and lipoprotein risk factors, their
value in clinical practice needs to be critically appraised
and appropriate guidelines developed for their pro-
posed use.
CONTENT: The National Academy of Clinical Biochem-
istry (NACB) convened a multidisciplinary expert
panel to develop laboratory medicine practice guide-
lines for a selected subset of these emerging risk factors
as applied in a primary prevention setting of heart dis-
ease and stroke. The NACB expert panel selected li-
poprotein subclasses and particle concentration, li-
poprotein(a), apolipoproteins A-I and B, high
sensitivity C-reactive protein (hsCRP), fibrinogen,
white blood cell count, homocysteine, B-type natri-
uretic peptide (BNP), N-terminal proBNP (NT-
proBNP), and markers of renal function as biomarkers
that fell within the scope of these guidelines.
CONCLUSIONS: Based on a thorough review of the pub-
lished literature, only hsCRP met all of the stated crite-
ria required for acceptance as a biomarker for risk as-
sessment in primary prevention.
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The purpose of this document is to present an Execu-
tive Summary of the National Academy of Clinical Bio-
chemistry (NACB)9 Laboratory Medicine Practice
Guidelines (LMPG) for utilization of emerging labora-
tory biomarkers of cardiovascular and stroke risk in a
primary prevention setting. The NACB is the scientific
academy of the AACC. An important activity of the
NACB is to develop laboratory medicine practice
guidelines to assist clinical and laboratory practice de-
cisions concerning patients at increased risk for specific
diseases.
BACKGROUND
In recent years, the number of new candidate risk
factors proposed as significant predictors of cardio-
vascular disease (CVD) and its complications has
grown considerably (Table 1). These biomarkers are
termed “emerging risk factors” because they are as-
sociated with an increased risk for CVD, but their
causative, independent, and quantitative contribu-
tions to CVD are not as well documented as dyslip-
idemia, high blood pressure, and smoking—the ma-
jor, longest established risk factors (1 ). An emerging
marker may not be necessarily a newly discovered
marker, but may be an existing one for which evi-
dence is only now available establishing it as effective
for independently identifying risk or for monitoring
treatment.
BIOMARKER ASSESSMENT
Several general principles are useful to bear in mind
when evaluating the utility of biomarker measure-
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ments in advancing science, guiding risk screening
strategies, and affecting clinical care.
The first step in the evaluation of a biomarker is an
assessment of whether its concentration is different in
persons affected by disease in comparison to those who
are not. Initial studies have typically used a case-
control design, and reporting of the results has focused
on the risks related specifically to the biomarker, with
secondary consideration of statistical adjustments.
Published reports at this phase may show relatively
strong estimates of relative risk for persons with con-
centrations of the new biomarker that are significantly
different in cases compared with controls.
A second step in the evaluation of a new biomarker
is the development of a body of evidence from case-
control and prospective studies that have evaluated the
new test. The prospective studies can include nested
case-control studies and full cohort investigations.
Evaluation is aided at this phase if the biomarker can be
measured by using previously collected and stored
samples, provided that measurements on aliquots yield
accurate and precise data. The storage of samples at
temperatures 70 °C has greatly facilitated such in-
vestigations. A nested case-control study with adequate
statistical power to address the question is an appropri-
ate cost-effective strategy. An ancillary issue at this
phase is to rigorously test whether the new biomarker
effects are present in multivariate statistical analyses
after appropriate corrections are performed for vari-
ables including age, sex, ethnicity, underlying diseases,
and the type and severity of CVD.
A third step in the evaluation of a new biomarker is
whether the measurement improves our ability to as-
sess risk above and beyond the current approaches. In
other words, can the new test improve the ability to
discriminate between future cases and noncases? Of
course, accurate assessment of the new marker value
can only be determined after correction for appropri-
ate confounders, and the marker can only be deemed
useful if it offers additional value over that provided by
existing risk algorithms (such as the Framingham Risk
Score (2 ) in the context of CVD). Unfortunately, many
investigations lack such information, which can make
it difficult to adequately evaluate the value of a new
biomarker.
Finally, reliable analytical methods must be avail-
able for the measurement of the intended biomarker.
GUIDELINE DEVELOPMENT
The NACB convened a multidisciplinary panel of ex-
perts to develop recommendations regarding the labo-
ratory measurement and clinical utility of a selected
number of emerging risk markers for use in primary
prevention of heart disease and stroke. The selection of
risk markers for evaluation and inclusion in these
guidelines was based on consensus of the expert panel
after systematically reviewing available evidence and
evaluating criteria of clinical usefulness, consistency of
epidemiologic data, improved predictive value, inde-
pendence from other factors, and available analytical
methods (3 ). Specific recommendations in these
NACB guidelines are based, whenever possible, on rel-
evant published information from prospective obser-
vational studies of initially healthy populations pub-
lished through February 2005. We did not consider
retrospective studies or studies of populations with ex-
isting vascular diseases, except in the case of evaluating
the use of biomarkers in secondary prevention (be-
cause fewer data are available in primary prevention
settings). The strength of scientific data supporting
each recommendation was characterized using the
scoring criteria adopted from the American Heart As-
sociation/American College of Cardiology, as summa-
rized in Table 2. For each recommendation, the desig-
nations I, IIa, IIb, and III describe the indications, and
the uppercase letters A, B, and C describe the weight of
evidence.
The NACB expert panel defined the following risk
markers as within the scope of these guidelines: high-
sensitivity C-reactive protein (hsCRP), fibrinogen,
white blood cell count (WBC), lipoprotein (Lp) sub-
classes and particle concentration, lipoprotein(a), apo-
lipoprotein A-I (apoA-I) and apoB, homocysteine
(Hcy), B-type natriuretic peptide (BNP), N-terminal
proBNP (NT-proBNP), and markers of renal function.
Table 1. Emerging risk factors for cardiovascular
disease.
C-reactive protein Interleukins (e.g., IL-6)
Serum amyloid A Vascular and cellular adhesion
molecules
Soluble CD40 ligand Leukocyte count
Fibrinogen Plasminogen activator
inhibitor 1
D-Dimer Tissue plasminogen activator
Factors V, VII, VIII Small dense LDL
Lipoprotein(a) Apolipoproteins A1 and B





Cystatin C Infectious agents
ApoE genotype Fibrinopeptide A
Remnant lipoproteins von Willebrand factor antigen
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The draft guidelines were posted on the NACB
website in September 2006 for public comment from
individuals, organizations, and other interested par-
ties. The guidelines were also presented at the 27th
Arnold O. Beckman Conference in Baltimore, Mary-
land, in October 2006. Public comments received
through these channels were carefully reviewed by the
committee and actions were taken to address them.
These responses are summarized in a supplemental
document at http://www.aacc.org/members/nacb/
LMPG/Pages/default.aspx.
Based on a thorough review of the published liter-
ature as detailed in the full guideline document (avail-
able at http://www.aacc.org/members/nacb/LMPG/
Pages/default.aspx), only hsCRP met all of the stated
criteria required for acceptance as a biomarker for risk
assessment in primary prevention.
As a result, the following recommendations for as-
sessing risk for CVD in primary prevention are made.
Inflammation Biomarkers and CVD Risk
CLINICAL SCIENCE
Recommendation 1
(a) After standard global risk assessment, if the 10-year
predicted risk is 5%, hsCRP should not be measured.
(Classification of recommendation: I; Level of ev-
idence: A)
(b) If the 10-year risk is 5% to 10%, it is expected
that 10% might be reclassified to a higher risk group
with the test. More information is needed on clinical
application, particularly in relation to longer-term life-
time risk prediction and selection of an appropriate
intervention (lifestyle/medical).
(Classification recommendation: II; Level of evi-
dence: B)
(c) If risk is intermediate (10%–20%) and uncer-
tainty remains as to the use of preventive therapies such
as statins or aspirin, then hsCRP measurement might
be useful for further stratification into a higher or lower
risk category.
(Classification of recommendation: I; Level of
evidence: A)
Recommendation 2
Therapies prescribed based on hsCRP concentrations
should be based on clinical judgment of the physician
because benefits of such treatment are uncertain.
(Classification of recommendation: IIb; Level of
evidence: B)
Recommendation 3
There are insufficient data that therapeutic monitoring
using hsCRP over time is useful to evaluate effects of
treatments in primary prevention.
(Classification of recommendation: III (against
use); Level of evidence: C)
Recommendation 4
The utility of hsCRP concentrations to motivate pa-
tients to improve lifestyle behaviors has not been dem-
onstrated.
(Classification of recommendation: IIb; Level of
evidence: C)
Recommendation 5
Evidence is inadequate to support concurrent mea-
surement of other inflammatory markers in addition
to hsCRP for coronary risk assessment.
(Classification of recommendation: IIb; Level of
evidence: C)
Table 2. American Heart Association/American College of Cardiology classification summary of indications.
I Conditions for which there is evidence and/or general agreement that a given procedure or treatment
is useful and effective
II Conditions for which there is conflicting evidence and/or a divergence of opinion about the
usefulness/efficacy of a procedure or treatment
IIa Weight of evidence/opinion is in favor of usefulness/efficacy
IIb Usefulness/efficacy is less well established by evidence/opinion
III Conditions for which there is evidence and/or general agreement that the procedure/treatment is not
useful/effective and in some cases may be harmful
Weight of evidence
A Data derived from multiple randomized clinical trials that involved large numbers of patients
B Data derived from a limited number of randomized trials that involved small numbers of patients or
from careful analyses of nonrandomized studies or observational registries
C Expert consensus as the primary basis for the recommendation
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POPULATION SCIENCE
1. The preponderance of evidence supports that higher
hsCRP, fibrinogen, and WBC are associated with in-
creased risk of cardiovascular events after adjustment
for other known risk factors.
CLINICAL SCIENCE/LABORATORY TESTING
Recommendation 1
Measurement of hsCRP should be done, in the fasting
or nonfasting state, in metabolically stable patients free
of infection or acute illness. If the hsCRP concentration
is 3 mg/L, it does not need to be repeated. If the value
is 3 mg/L, repeat the measurement at least 2 weeks
later in metabolically stable state, free of infection or
acute illness. The lower of the 2 results should be con-
sidered the patient’s value. If hsCRP is 10 mg/L this
might relate to CVD risk. Other conditions such as ac-
tive infection or inflammation or inflammatory disor-
ders might be responsible. Extensive evaluations with
imaging tests or other testing for these patients is not
recommended unless pertinent history and physical
exam findings are present, or if pursuing normal prac-
tice for age-appropriate population screening.




Of the examined inflammatory markers for assessing
CVD risk, hsCRP has the analyte and assay character-
istics most appropriate for use in clinical practice.
(Classification of recommendation: I; Level of ev-
idence: A)
Recommendation 2
There are sufficient data that fibrinogen is an indepen-
dent marker of CVD risk; however, because of analyt-
ical concerns, insufficient assay standardization, and
uncertainty in identifying treatment strategies, mea-
surement is not recommended for this application.
(Classification of recommendation: III; Level of
evidence: A)
Recommendation 3
There are sufficient data that WBC is an independent
marker of CVD risk; however, because utility in reclas-
sifying risk level and identifying treatment strategies is
not known, measurement is not recommended for this
application.
(Classification of recommendation: III; Level of
evidence: C)
Recommendation 4
hsCRP results, regardless of the method used, should
be expressed as mg/L.
(Classification of recommendation: I; Level of ev-
idence: C)
Recommendation 5
hsCRP using standardized assays categorizes patients
as follows:
(a) Low risk 1.0 mg/L
(b) Average risk 1.0 –3.0 mg/L
(c) High risk 3.0 mg/L
(d) Very high risk 10.0 mg/L
(Classification of recommendation: IIa; Level of
evidence: A)
Recommendation 6
Manufacturers of diagnostic assays for hsCRP should
follow approved value transfer protocols to ensure that
standardized assays are used for vascular risk assess-
ment.
(Classification of recommendation: I; Level of ev-
idence: C)
Recommendation 7
Caution is recommended in application of the hsCRP
categorization in recommendation 5 for risk predic-
tion in certain populations such as nonwhites and the
elderly, as the clinical utility is less established.
(Classification of recommendation: IIa; Level of
evidence: C)
LIPOPROTEIN SUBCLASSES AND PARTICLE CONCENTRATION
AND CVD RISK
Recommendation 1
Lipoprotein subclasses, especially the number or con-
centration of small dense LDL particles, have been
shown to be related to the development of initial coro-
nary heart disease events, but the data analyses of exist-
ing studies are generally not adequate to show added
benefit over standard risk assessment for primary
prevention.
(Classification of recommendation: III (lipopro-
tein subclass determination is not recommended);
Level of Evidence: A)
Recommendation 2
There are insufficient data that measurement of li-
poprotein subclasses over time is useful to evaluate the
effects of treatments.
(Classification of recommendation: III; Level of
evidence: C)
Recommendation 3
Several methods are available to assess lipoprotein sub-
classes. Standardization is needed for this technology.
(Classification of recommendation: IIa; Level of
evidence: C)
NACB Guidelines for Emerging Cardiac Biomarkers Preamble
Clinical Chemistry 55:2 (2009) 381
LIPOPROTEIN(a) AND CVD RISK
Recommendation 1
Lp(a) screening is not warranted for primary preven-
tion and assessment of cardiovascular risk.
(Classification of recommendation: III (against
measurement); Level of evidence: A)
Recommendation 2
If risk is intermediate (10%–20%) and uncertainty re-
mains as to the use of preventive therapies such as st-
atins or aspirin, then Lp(a) measurement may be done
at the physician’s discretion.
(Classification of recommendations: IIb; Level of
evidence: C)
Recommendation 3
After global risk assessment, Lp(a) measurements in
patients with a strong family history of premature car-
diovascular disease may be useful for identifying indi-
viduals having a genetic predisposition of cardiovascu-
lar disease.
(Classification of recommendation: IIb; Level of
evidence: C)
Recommendation 4
The benefits of therapies based on Lp(a) concentra-
tions are uncertain. If both Lp(a) and LDL cholesterol
are highly increased, an attempt can be made at the
physician’s discretion to lower Lp(a) value by lowering
the increased LDL cholesterol.
(Classification of recommendation: IIb; Level of
evidence: C)
Recommendation 5
There is insufficient evidence to support therapeutic
monitoring of Lp(a) concentrations for evaluating the
effects of treatment.
(Classification of recommendation: III (against
measurement); Level of evidence: C)
Recommendation 6
Population routine testing for small size apolipopro-
tein(a) is not warranted.
(Classification of recommendation: IIb; Level of
evidence: C)
apoA-I, apoB, AND CVD RISK
Recommendation 1
The first step to monitor efficacy of lipid-lowering
therapies is to measure LDL cholesterol (and non-HDL
cholesterol in patients with increased triglycerides).
(Classification of recommendation: I; Level of ev-
idence: A)
Recommendation 2
Although apoB measures atherogenic lipoproteins and
is a good predictor of CVD risk (equal at least to LDL
cholesterol and non-HDL cholesterol), it is only a mar-
ginally better predictor than the current lipid profile
and should not be routinely measured at this time for
use in global risk assessment.
(Classification of recommendation: IIa (against
measurement); Level of evidence: B)
Recommendation 3
Measurement of apoB can be used to monitor efficacy
of lipid-lowering therapies as an alternative to non-
HDL cholesterol.
(Classification of recommendation: IIb; Level of
evidence: B)
Recommendation 4
The apoB/apoA-I ratio can be used as an alternative to
the usual total cholesterol/HDL cholesterol ratio to de-
termine lipoprotein-related CVD risk.
(Classification of recommendation: IIa; Level of
evidence: A)
Recommendation 5
Manufacturers of apoB and apoAI assays should estab-
lish traceability to accepted standards to assure reliable
and comparable results.
(Classification of recommendation: IIa; Level of
evidence: C)
MARKERS OF RENAL FUNCTION AND CVD RISK
Recommendation 1
Chronic kidney disease (CKD) testing is not routinely
recommended if the 10-year predicted risk is 5%
without specific CKD or CVD risk factors, either for
CKD detection or CVD risk assessment.
(Classification of recommendation: III (against
routine measurement); Level of evidence: C)
Recommendation 2
CKD testing, including serum creatinine for glomeru-
lar filtration rate (GFR) estimation and microalbumin-
uria, for primary prevention should be performed for
all individuals with hypertension, diabetes mellitus,
family history of CKD, and those at intermediate risk
(10%–20%) for CVD. In addition, measurement of se-
rum creatinine for GFR estimation should be per-
formed in all individuals 65 years old. Individual de-
cisions are recommended in those with other CKD risk
factors.
(Classification of recommendation: IIa; Level of
evidence: B)
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Recommendation 3
Manufacturers of creatinine assays should comply with
the most recent recommendations for standardization
and other performance characteristics recommended
by the National Kidney Disease Education Program
(NKDEP). Calculation of estimated GFR from creati-
nine values should be consistent with the most recent
NKDEP recommendations.
(Classification of recommendation: I; Level of ev-
idence: C)
Recommendation 4
Cystatin C may be a more powerful predictor of car-
diovascular events than estimated GFR (eGFR) calcu-
lation based on creatinine. Research should be con-
ducted to examine if interventions based on cystatin C
measurements for risk stratification in individuals with
diminished estimated GFR will provide added clinical
benefit.
(Classification of recommendation: IIa; Level of
evidence: C)
Recommendation 5
Properly designed studies focusing on the role of kid-
ney disease markers (microalbumin, eGFR, and cysta-
tin C) should be conducted to characterize the utility of
these markers in the global assessment of CVD risk in
the primary prevention setting.
(Classification of recommendation: I; Level of ev-
idence: C)
HOMOCYSTEINE AND CVD RISK
The clinical application of homocysteine measurement
for risk assessment of primary prevention of CVD is
uncertain given that several trials investigating folic
acid and vitamin B supplementation published after
our literature review indicated no benefit or lowering
of CVD risk. A more detailed review of the literature for
homocysteine appears in the online version of this
guideline.
Recommendation 1
Hcy concentrations (mol/L) derived from standard-
ized assays categorize patients as follows:
Desirable 10
Intermediate (low to high) 10 to 15
High 15 to 30
Very high 30
(Classification of recommendation: IIa; Level of
evidence: C)
Recommendation 2
The analytical performance goal for clinical usefulness
for measurement of Hcy should be 10% for bias,
5% for precision, and 18% for total error. Manu-
facturers of diagnostic assays for Hcy should follow ap-
proved value transfer protocols to ensure that stan-
dardized assays are used for vascular risk assessment.
(Classification of recommendation: IIa; Level of
evidence: C)
NATRIURETIC PEPTIDES (BNP AND NT-proBNP) AND CVD RISK
Recommendation 1
Increased BNP or NT-proBNP concentrations are as-
sociated with increased mortality in the next 2–7 years
in community-based populations. However, the bene-
fits of therapy based on these measurements are uncer-
tain. Measurement for CVD risk assessment in the pri-
mary prevention setting is unwarranted.
(Classification of recommendation: III (against
measurement); Level of evidence: B)
Recommendation 2
More research should be performed to determine if
BNP and NT-proBNP measurements are useful in
identifying individuals who are at increased risk of de-
veloping heart failure and might benefit from therapies
for prevention of heart failure and cardiovascular dis-
ease.
(Classification of recommendation: I; Level of ev-
idence: C)
Recommendation 3
Manufacturers of reagents and kits for measurement of
BNP or NT-proBNP should be in compliance with cur-
rent specifications developed by government and pro-
fessional organizations, such as the IFCC.
(Classification of recommendation: I; Level of ev-
idence: C)
Recommendation 4
Laboratorians, clinicians, and manufacturers involved
in using and/or producing natriuretic peptide assays
must work together to ensure that all stakeholders are
properly educated regarding preanalytical (e.g., biolog-
ical variation, specimen stability), analytical (the im-
pact of various proBNP-derived peptides forms on as-
says, methodological variation of BNP results), and
postanalytical (appropriate reference intervals, deci-
sion limits, and confounding clinical conditions) is-
sues.
(Classification of recommendation: I; Level of
evidence: C)
Guideline Implementation
Adoption of these guidelines is voluntary. The litera-
ture continues to grow with published reports provid-
ing new information on these and other emerging
biomarkers for heart disease and stroke. It is increas-
ingly important that as these candidate biomarkers
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emerge, their value for possible clinical application
along with measurement issues be properly evaluated.
As a result of this continuous expanding body of re-
search, the current NACB guidelines will undoubtedly
require continuous review and updating as knowledge
and understanding of existing and new biomarkers for
primary prevention of heart disease and stroke emerge.
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